title: Gene transfer in human skin with different pseudotyped HIV-based vectors.
abstract: Pseudotyping lentiviral vector with other viral surface proteins could be applied for treating genetic anomalies in human skin. In this study, the modification of HIV vector tropism by pseudotyping with the envelope glycoprotein from vesicular stomatitis virus (VSV), the Zaire Ebola (EboZ) virus, murine leukemia virus (MuLV), lymphocytic choriomeningitis virus (LCMV), Rabies or the rabies-related Mokola virus encoding LacZ as a reporter gene was evaluated qualitatively and quantitatively in human skin xenografts. High transgene expression was detected in dermal fibroblasts transduced with VSV-G-, EboZ- or MuLV-pseudotyped HIV vector with tissue irregularities in the dermal compartments following repeated injections of EboZ- or LCMV-pseudotyped vectors. Four weeks after transduction, double-labeling immunofluorescence of beta-galactosidase and involucrin or integrin beta1 demonstrated that VSV-G-, EboZ- or MuLV-pseudotyped HIV vector effectively targeted quiescent epidermal stem cells which underwent terminal differentiation resulting in transgene expression in their progenies. Among the six different pseudotyped HIV-based vectors evaluated, VSV-G-pseudotyped vector was found to be the most efficient viral glycoprotein for cutaneous transduction as demonstrated by the highest level of beta-galactosidase expression and genome copy number evaluated by TaqMan PCR.
authors.affiliation: Kao Biological Science Laboratories, Haga, Tochigi, Japan. hachiya.akira@kao.co.jp
authors.forename: A
authors.initials: A
authors.lastname: Hachiya
authors.forename: P
authors.initials: P
authors.lastname: Sriwiriyanont
authors.forename: A
authors.initials: A
authors.lastname: Patel
authors.forename: N
authors.initials: N
authors.lastname: Saito
authors.forename: A
authors.initials: A
authors.lastname: Ohuchi
authors.forename: T
authors.initials: T
authors.lastname: Kitahara
authors.forename: Y
authors.initials: Y
authors.lastname: Takema
authors.forename: R
authors.initials: R
authors.lastname: Tsuboi
authors.forename: R E
authors.initials: RE
authors.lastname: Boissy
authors.forename: M O
authors.initials: MO
authors.lastname: Visscher
authors.forename: J M
authors.initials: JM
authors.lastname: Wilson
authors.forename: W M
authors.initials: WM
authors.lastname: James
authors.forename: G P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000818:Animals; D020405:Dermis / Q000378:metabolism*; D029043:Ebolavirus / Q000235:genetics; D004926:Escherichia coli / Q000201:enzymology; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006678:HIV / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D009052:Leukemia Virus, Murine / Q000235:genetics; D008217:Lymphocytic choriomeningitis virus / Q000235:genetics; D051379:Mice; D008819:Mice, Nude; D018613:Microscopy, Confocal; D011820:Rabies virus / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D012871:Skin Diseases / Q000378:metabolism / Q000628:therapy; D014161:Transduction, Genetic / Q000379:methods*; D019076:Transgenes; D014183:Transplantation, Heterologous; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000235:genetics*; D001616:beta-Galactosidase / Q000235:genetics
chemical_list: D014759:Viral Envelope Proteins; D001616:beta-Galactosidase